Biosimilar Policy Update: Extrapolation Looks Like Default Approach
This article was originally published in RPM Report
Executive Summary
As FDA nears the first review deadlines for biosimilar applications, some policy points are coming into sharper focus. Clinical studies for immunogenicity sound like a benchmark requirement, while extrapolation of indications also seems like the agency’s default position.